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miRNA-205 targets VEGFA and FGF2 and regulates
resistance to chemotherapeutics in breast cancer
Y Hu*,1,2,4, Y Qiu1, E Yagüe3, W Ji2, J Liu1 and J Zhang*,1,2,4
MicroRNAs (miRNAs) have critical roles in regulating cancer cell survival, proliferation and sensitivity to chemotherapy. The
potential application of using miRNAs to predict chemotherapeutic response to cancer treatment is highly promising. However, the
underlying mechanisms of chemotherapy response control by miRNAs remain to be fully identified and their prognostic value has
not been fully evaluated. Here we show a strong correlation between miR-205 expression and chemosensitivtiy to TAC (docetaxol,
doxorubicin plus cyclophosphamide), a widely-used neoadjuvant chemotherapy (NAC) regimen, for breast cancer patients. High
level of miR-205 predicted better response to TAC regimen NAC in breast cancer patients. We foundmiR-205 downregulated in both
MCF-7/A02 and CALDOX cells, two drug-resistant derivatives of MCF-7 and Cal51 cells, and its ectopic expression led to an
increase in apoptosis resensitization of both drug-resistant cell lines to doxorubicin and taxol. We further show that miR-205
directly binds VEGFA and FGF2 mRNA 3′-UTRs and confirm that miR-205 levels are negatively correlated with VEGFA and FGF2
mRNA expression in breast cancer patients. Adding VEGFA and FGF2 exogenously to chemosensitive breast cancer cells and
chemoresistant cells with miR-205 overexpression led to drug resistance. Consistently, low VEGFA and FGF2 expression
correlated with better response to NAC in breast cancer patients. In addition, inhibition of tumor growth and resensitization to
doxorubicin were also observed in mouse tumor xenografts from cells overexpressing miR-205. Taken together, our data suggest
that miR-205 enhances chemosensitivity of breast cancer cells to TAC chemotherapy by suppressing both VEGFA and FGF2,
leading to evasion of apoptosis. MiR-205 may serve as a predictive biomarker and a potential therapeutic target in breast cancer
treatment.
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Despite the progress in early diagnosis, breast cancer remains
the most common cancer in women worldwide.1 Neoadjuvant
chemotherapy (NAC) is one of the most crucial factors for
tumor burden reduction and successful breast-conserving
surgery. In addition, using chemotherapy in the neoadjuvant
setting allows monitoring in vivo tumor response to
chemotherapeutics,2,3 and analyzing residual disease after
NAC may reveal novel therapeutic targets.4
Generally, only a fraction of breast cancer patients achieve
full response to NAC.5,6 Unfortunately, there is no reliable
method for predicting chemotherapeutic responders from non-
responders,7and there is an urgent need to stratify these
patients in order to avoid unnecessary chemotherapy side
effects. Recent efforts have focused on the characterization of
biomarkers able to predict response to NAC, with the aim to
tailor patient-care programs, reduce chemotherapy-induced
morbidity or mortality and identify novel targets to be used in
the development of innovative and more efficient therapies for
the treatment of breast carcinoma.
MicroRNAs (miRNAs), a class of highly conserved, short,
non-protein-coding RNAs that negatively regulate gene
expression, have emerged as crucial regulators of the drug
response by modulating dug efflux, cell apoptosis, epithelial–
mesenchymal transition (EMT) and cancer stem cells.8–10
Previous studies have revealed that numerous miRNAs are
upregulated or downregulated in breast cancer, contributing
to the initiation and development of the disease, as well as
its drug sensitivity.11–13 For instance, overexpression of
miRNA-451 sensitizes breast cancer cells to doxorubicin,14
and upregulation of miRNA-21 is associated with acquired
trastuzumab resistance.15 Moreover, we have recently
reported that the miR-106b-93-25 cluster leads to activation
of EMT transition and resistance to doxorubicin and taxol.16,17
However, predictive miRNA signatures of NAC response
remain to be found and fully validated.
We previously reported that miR-205 may function as a
tumor suppressor, as its expression is reduced in breast
tumors. Importantly, experimental restoration of miR-205
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expression in breast cancer cells inhibits cell proliferation and
promotes apoptosis.18 In this study, we show that high levels of
miR-205 predict sensitivity to TAC (docetaxol, doxorubicin
and cyclophosphamide) regimen in breast cancer patients.
MiR-205 is downregulated in drug-resistant derivates of
MCF-7 and Cal51 cells and its ectopic expression resensitizes
both drug-resistant cells to doxorubicin and taxol. We
demonstrate that miR-205 targets vascular endothelial growth
factor A (VEGFA) and fibroblast grow factor-2 (FGF2),
resulting in decreased phosphatidylinositol 3-kinase (PI3K)/
Akt signaling pathway activity and increased apoptosis upon
chemotherapy. Therefore, miR-205 may be used as a
predictive biomarker for TAC regimen and a potential
therapeutic target in breast cancer treatment.
Results
miR-205 expression levels correlate with NAC response
in breast cancer patients. In order to investigate the
correlation of miR-205 expression with NAC response, we
collected 30 breast cancer tissue samples from patients
before receiving TAC (Table 1), an anthracycline and taxane-
based regimen widely used as neoadjuvant treatment of
breast cancer.19 TAC (docetaxol, 75 mg/m2, doxorubicin,
50 mg/m2 and cyclophosphamide, 500 mg/m2) was adminis-
tered every 3 weeks for 6 cycles as NAC. Standard RECIST
guidelines were used to evaluate clinical and pathological
response. We performed a linear regression and Spearman
rank test and obtained a positive correlation between
miR-205 expression, detected by reverse transcription
quantitative real-time PCR (qRT-PCR) and NAC response
rate, calculated by the alterations in greatest tumor diameter
(rs= 0.4305, P=0.0175) (Figure 1a). Thus miR-205 expres-
sion correlates with NAC response.
miR-205 is downregulated in drug-resistant breast can-
cer cells. To confirm the positive correlation between
miR-205 and TAC response shown in breast cancer patients,
we further analyzed its expression in two pairs of chemo-
sensitive and chemoresistant breast cancer cell lines. MCF-7/
A02 and CALDOX have been derived from chemosensitive
MCF-7 and Cal51 cells, respectively,20,21 and show a tradi-
tional multidrug-resistant phenotype with cross-resistance
to a wide range of structurally and functionally unrelated
Table 1 Clinical information of the 30 patients included in the study
Characteristics Number of patients %
Age 53 (27–67) years
≤ 35 2 6.7
35–55 16 53.3
455 12 40.0
Histology
Infiltrating ductal carcinoma 12 40.0
Infiltrating (mixed) carcinoma 14 46.7
Others 4 13.3
TNM stage
II 7 23.3
IIIA 19 63.3
IIIB–IV 4 13.3
Estrogen receptor status
Negative 13 43.3
Positive 17 56.7
Progesterone receptor status
Negative 20 66.7
Positive 10 33.3
Her2 status
Negative 19 63.3
Positive 11 36.7
Figure 1 High expression of miR-205 correlates with better chemotherapeutic
response. (a) Expression levels of miR-205 in breast cancer patients (n= 30) who
received TAC regimen NAC were determined by qPCR. Spearman rank test was
used for the correlation between miR-205 and NAC response rate determined as
(1− greatest tumor diameter after NAC/greatest tumor diameter before NAC) ×
100%. The trend of the correlation is indicated with a line calculated by linear
regression. (b) miR-205 expression in pairs of drug-sensitive and -resistant MCF-7
(left panel) and Cal51 (right panel) cells determined by qPCR. (c) miR-205 expression
in pairs of drug-sensitive and -resistant K562, MTMEC, HL60 and BJAB cells. miR
expression determined by qPCR was normalized to that of RNU6 RNA. Data
represent the average±S.D. of three independent experiments (*Po0.05)
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drugs (Supplementary Tables S1 and S2). We found miR-205
downregulated in both MCF-7/A02 and CALDOX cells by
approximately 90 and 75%, respectively (Figure 1b). Similar
results were also observed in other pairs of sensitive/resistant
cancer cell lines such as those derived from K562, MTMEC,
HL60 and BJAB cells17,21,22 (Figure 1c), although only breast
cancer drug-resistant MTMECs showed similar diminished
miR-205 levels as those found in the other breast cancer cell
lines (Figure 1b). Thus miR-205 is downregulated in
multidrug-resistant cell lines.
Overexpression of miR-205 restores drug sensitivity by
promoting apoptosis in breast cancer cells. As miR-205
is downregulated in drug-resistant breast cancer cell lines,
we hypothesized that, if it would contribute to the drug-
resistant phenotype, its ectopic expression might restore
Figure 2 miR-205 overexpression restores drug sensitivity and promotes apoptosis in breast cancer cells. Drug-resistant MCF-7/A02 and CALDOX cells were stably
transfected with a lentivirus carrying an expression vector for miR-205, generating MCF-7/A02-miR-205 and CALDOX-miR-205 cells, respectively. Control cells, MCF-7/A02-NC
and CALDOX-NC were transfected with the empty vector (pGLV2-U6-Puro). (a) Expression of miR-205 in transfected cells determined by qPCR and normalized to RNU6
expression. (b) IC50 values of doxorubicin and taxol (3-day treatments) in transfected cells. (c) Effect of miR-205 on drug resistance. Cells were treated with doxorubicin (15 μM
for MCF-7/A02 and 1 μM for CALDOX) and taxol (0.25 μM for MCF-7/A02 and 2.5 nM for CALDOX) for 7 days, and the cells were stained with crystal violet. Dye was solubilized
and the optical density at 592 nm was measured. (d) Transfected drug-resistant cells were treated with taxol (0.25 μM for MCF-7/A02 and 2.5 nM for CALDOX) for 48 h. Annexin
V/propidium iodide staining was detected by flow cytometry. Representative plots of three independent experiments are shown, left panels. Quantitative data show the average
percentage of annexin V-positive cells (both in early apoptosis, lower right quadrant, and late apoptosis, upper right quadrant) of three independent experiments, right panels.
(e) Caspase-3/7 and caspase-9 activities in miR-205-transfected MCF-7/A02 (upper histograms) and CALDOX cells (lower histograms) after 48-h taxol treatment. (f) Expression
levels of cleaved PARP and cleaved caspase-3 in drug-resistant CALDOX cells were determined by western blotting after 2.5 nM taxol treatment for 48 h. (g) Expression levels of
Bax and survivin in mir-205-transfected drug-resistant cells determined by qPCR and normalized to RPS14 expression. (h) Expression levels of pAKT, AKT, Bax and survivin in
miR-205-transfected drug-resistant cells determined by western blotting. Numerical data represent mean± S.D. based on three independent experiments (*Po0.05). Pictorial
data show representatives of three independent experiments
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drug sensitivity. To test this hypothesis, we generated stable
MCF-7/A02 and CALDOX cells overexpressing miR-205 by
lentiviral transfection (MCF-7/A02-miR-205 and CALDOX-
miR-205, respectively). Cells transfected with empty vector
(MCF-7/A02-NC and CALODX-NC) were used as control.
MiR-205 expression was upregulated 24-fold in MCF-7/A02-
miR-205 cells and 32-fold in CALDOX-miR-205 cells
(Figure 2a). Drug sensitivity assays indicated that the
doxorubicin IC50 values of miR-205 overexpressing cells
decreased between 74 and 82% (74.4% in MCF-7/A02-
miR-205 cells and 81.9% in CALDOX-miR-205 cells).
Equally, miR-205-overexpressing cells were more sensitive
to taxol, and the IC50 values of miR-205-overexpressing cells
decreased between 56 and 84% (84.2% in MCF-7/A02-
miR-205 cells and 56.8% in CALDOX-miR-205 cells;
Figure 2b and Supplementary Figure S1). Moreover, to
evaluate the efficacy of miR-205 overexpression on drug
resistance, defined as proliferation in the presence of toxic
drug concentrations, we stained cell cultures with crystal
violet, as a surrogate for cell mass,23 after 1 week treatment
(drug concentrations and time points were determined
empirically in a series of preliminary experiments). MiR-205
restoration decreased cell proliferation in the absence of drug
by 24–37% (Figure 2c), and cell cycle analysis showed a
significant arrest and accumulation of cells in the G0/G1
phase (Supplementary Figure S1B), which is consistent with
data in human osteosarcoma24 and thyoid carcinoma.25
Moreover, miR-205 impaired proliferation to a much higher
extent in the presence of doxorubicin or taxol (reduction
between 75 and 91%; Figure 2c). Thus overexpression of
miR-205 restores sensitivity to doxorubicin and taxol in drug-
resistant breast cancer cells.
Figure 2 Continued
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miR-205 overexpression promotes cell apoptosis,
induces caspase activity and modulates apoptosis-
related proteins. Next we asked whether the drug sensitivity
rescue by miR-205 on chemoresistant breast cancer cells
was mediated by promoting cell apoptosis. For this, we used
taxol, a widely used microtubule poison and activator of the
apoptotic cascade.26 Annexin V staining indicated that in both
drug-resistant cells ectopic expression of miR-205 increased
the percentage of cells undergoing apoptosis after taxol
treatment (Figure 2d). As CALDOX cells are more sensitive to
taxol than MCF-7/A02 cells, the concentration of taxol used
was 0.25 μM for MCF-7/A02 and 2.5 nM for CALDOX cells.
Approximately 20% of MCF-7/A02-miR-205 cells were in the
early stages of apoptosis (positive annexin V and negative
propidium iodide), whereas approximately 18% of CALDOX-
miR-205 cells were already in the late stage of apoptosis
(positive for both annexin V and propidium iodide) after 48-h
taxol treatment (Figure 2d).
As caspases are keymediators of apoptosis,27 we analyzed
the activation of both initiator and effector caspases in
miR-205-overexpressing cells in response to taxol treatment.
Both caspase 9 and caspase 3/7 activities increased between
2- and 4.5-fold after taxol treatment in drug-resistant cells
overexpressing miR-205 when compared with the control cells
(Figure 2e). It is also noteworthy that miR-205 overexpression
increased caspase activity in both drug-free cell lines,
although the activation due to drug treatment was much
higher (Figure 2e). Caspase 3, the effector caspase in the
apoptotic cascade, is activated through cleavage by caspase-
9 as a result of increased mitochondrial permeability and
release of cytochrome c. PARP is cleaved by activated
caspase-3 and cleavage of caspase-3 and PARP are
signature events in apoptosis.28 Consistent with the increased
apoptosis in the taxol-treated miR-205-overexpressing cells,
we observed a marked increase in the levels of cleavage of
caspase-3 and PARP in CALDOX-miR-205 cells, especially
after taxol treatment (Figure 2f). As MCF-7 cells lack caspase
3, these activities were not measured in MCF-7/A02 cells.29
The induction of apoptotic cell death alters the ratios
of prosurvival and proapoptotic proteins. Hence, we evaluated
the expression level of survivin, a survival gene, and pro-
apoptotic Bax. RT-qPCR and western blotting results revealed
that overexpressing miR-205 repressed survivin and pro-
moted Bax expression in drug-resistant cells (Figures 2g
and h). The PI3K/AKT signaling pathway is frequently dys-
regulated in human cancer and has been implicated in
chemoresistance.30,31 We also observed that the induction
of cell apoptosis by miR-205 overexpression in both drug-
resistant cells was associated with a significant reduction in
AKT phosphorylation, suggesting a decrease in PI3K activity
(Figure 2h). Thus overexpression of miR-205 in drug-resistant
cells promotes apoptosis by upregulation of Bax and down-
regulation of survivin and the AKT pathway.
miR-205 directly targets VEGFA and FGF2 and negatively
regulates their expression. miR-205 has recently been
reported to increase radiosensitivity and enhance EMT via
targeting ZEB1 in breast cancer SUM159, MCF-7 and MDA-
MB-231 cell lines.32,33 However, we did not observe any
regulation of ZEB-1 upon expression of miR-205 in either
drug-resistant MCF-7/A02 or CALDOX cells (Supplementary
Figures S2A and B). Moreover, we also compared ZEB-1
expression in both pairs of naive and drug-resistant deriva-
tives. Although ZEB-1 expression was highly upregulated in
MCF-7/A02 with respect to MCF-7 cells, ZEB-1 levels were
not significantly elevated in CALDOX cells (Supplementary
Figures S2A and B). Thus the lack of correlation between
ZEB-1 and miR-205 expression levels suggests that the
restoration of chemosensitivity by miR-205 in MCF-7/A02 and
CALDOX cells is ZEB-1 independent.
Bioinformatic analysis indicates that both VEGFA and
FGF2 are potential targets for miR-205 (Figure 3a), and this
has been confirmed for VEGFA in osteosarcoma24, thyroid
cancer25 and breast cancer MDA-MB-231 cells.34 VEGFA and
FGF2 promote therapy resistance in a number of cancers35–38
and, reassuringly, we have confirmed their overexpression
both at the mRNA and protein levels in both MCF-7/A02 and
CALDOX cells (Figure 3b). In addition, experimental expres-
sion of miR-205 in drug-resistant cells led to a downregulation
of both VEGFA and FGF2 (Figure 3c), confirming the negative
correlation between miR-205 and VEGFA/FGF2 expression.
To verify whether miR-205 is capable of regulating FGF2
and VEGFA expression via the binding sites in their 3′-UTRs
(Figure 3a), each 3′-UTR containing the predicted miR-205
binding site was cloned downstream of the firefly luciferase
coding region in the pMirTarget luciferase vector, resulting in
pMirTarget-VEGFA and pMirTarget-FGF2, respectively. We
transiently transfected cells overexpressing miR-205 with
pMirTarget-VEGFA or pMirTarget-FGF2, together with a
Renilla luciferase expressing plasmid to normalize for trans-
fection efficiency. We hypothesized that luciferase expression
would decrease in cells overexpressing miR-205 when
transfected with the reporter plasmid incorporating VEGFA
3′-UTR or FGF2 3′-UTR but not in the control. Indeed, an
approximately 40% reduction in luciferase expression was
observed in both MCF-7/A02-mir-205 versus MCF-7/A02-NC
and CALDOX-mir-205 versus CALDOX-NC when transfected
with pMirTarget-VEGFA. In addition, an approximately 35%
reduction in luciferase expression was also observed in both
MCF-7/A02-mir-205 versus MCF-7/A02-NC and CALDOX-
mir-205 versus CALDOX-NC when transfected with
pMirTarget-FGF2. However, no changes in luciferase expres-
sion were observed in the same cells transfected with the
pMirTarget-ev control vector (Figure 3d). Thus miR-205 binds
VEGFA and FGF2 mRNA 3′-UTRs and decreases their
expression in breast cancer cells.
To confirm the negative correlation between the decreased
VEGFA/FGF2 and enhanced miR-205 observed in breast
cancer cell lines, we further analyzed the expression of
VEGFA/FGF2 by quantitative PCR in the 30 patient samples
that show positive correlation between miR-205 expression
and response to TAC (Figure 1a). We found that both the
expression of VEGFA and FGF2 showed a negative correla-
tion with miR-205 levels in these 30 patients (rs=− 0.4851,
P= 0.0078 for VEGFA and miR-205, rs=− 0.38, P= 0.0349
for FGF2 and miR-205; Figure 3e). Additionally, we found
that high VEGFA/FGF2 level was associated with poorer
response to TAC regimen in these 30 patients, although
the correlation between VEGFA and NAC response rate did
not reach statistical significance, likely because of small
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Figure 3 Identification of VEGFA and FGF2 mRNAs as direct targets of miR-205 in breast cancer cells. (a) Annealing of miR-205 to VEGFA and FGF2 mRNA 3′-UTRs
according to the microRNA.org database. (b) VEGFA and FGF2 expression at mRNA (qPCR; left panels) and cytokine levels (ELISA; right panels) in drug-sensitive and -resistant
breast cancer cells. (c) Expression levels of VEGFA and FGF2 in drug-resistant cells after stable expression of miR-205 or empty vector control (NC) at mRNA (qPCR; left panels)
and protein levels (ELISA; right panels). (d) miR-205 targets VEGFA and FGF2 mRNAs. Normalized firefly luciferase activity from the reporter with the VEGFA 3′-UTR
(pMirTarget-VEGFA), FGF2 3′-UTR (pMirTarget-FGF2) or the empty vector (pMirTarget-ev) after transient transfection into cells overexpressing miR-205 or control (NC) cells. In
all cases, cells were co-transfected with a Renilla luciferase expression vector to normalize for transfection efficiency. Numerical data represent mean± S.D. based on three
independent experiments (*Po0.05). (e) Inverse correlation between miR-205 and VEGFA (left panel)/FGF2 (right panel) in breast cancer (n= 30) as determined by Spearman
rank test. The trend of the correlation is indicated with a line calculated by linear regression. (f) Expression levels of VEGFA (left panel) and FGF2 (right panel) in breast cancer
patients (n= 30) who received TAC regime NAC were quantitated by qPCR. Spearman rank test was used for depicting the correlation between mRNA and NAC response rate
determined as (1− greatest tumor diameter after NAC/greatest tumor diameter before NAC) × 100%. The trend of the correlation is indicated with a line calculated by linear
regression
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sample size (Figure 3f). Collectively, these data suggest that
the loss of miR-205 induces VEGFA/FGF2 expression, thus
conferring chemoresistance in breast cancer.
Repression of VEGFA and FGF2 in drug-resistant cells is
essential for miR-205-induced restoration of chemosen-
sitivity. To further verify whether the phenotype observed
after miR-205 overexpression was due to downregulation
of VEGFA and FGF2, a rescue methodology was adopted.
For this, MCF-7/A02-miR-205 and CALDOX-miR-205 cells
were treated with doxorubicin or taxol in the presence or
absence of VEGFA/FGF2. The addition of either VEGFA or
FGF2 significantly increased the doxorubicin IC50 values
of miR-205-overexpressing cells between 2.31- and 4.24-fold
(Figure 4a). Equally, miR-205-overexpressing cells were
more resistant to taxol in the presence of VEGFA/
FGF2, the IC50 values increasing between 1.49- and
2.12-fold (Figure 4a and Supplementary Figure S3A). In
agreement with the raised IC50 values, lowered caspase-3/7
and caspase-9 activities were observed in both miR-205-
overexpressing drug-resistant cells in the presence of
VEGFA/FGF2 after taxol treatment (Figure 4b). More-
over, the addition of VEGFA/FGF2 partially restored PI3K
activity and survivin expression, which were abolished by
Figure 3 Continued
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miR-205 overexpression, and also decreased Bax expres-
sion, which was induced by miR-205 overexpress-
ion (Figure 4c). Thus the chemo-sensitizing effect of
miR-205 in breast cancer depends on VEGFA/FGF2
downregulation.
To further confirm that PI3K activity is involved in the
miR-205/VEGFA and FGF2 axis to regulate chemosensitivity
of breast cancer cells, MCF-7/A02 and CALDOX cells were
treated with LY294002, a well-characterized selective PI3K/
AKT inhibitor. Similar to miR-205 overexpression, blocking
PI3K/AKT signaling was accompanied by a resensitization of
drug-resistant MCF-7/A02 and CALDOX cells to taxol, with an
increment of apoptotic levels by 20% (Figure 4d). Measure-
ment of caspase-3/7 and caspase-9 activities indicated an
increase after taxol treatment in both drug-resistant cells when
treated with LY294002 (Figure 4e). In addition, LY294002
treatment also enhanced Bax and reduced survivin expres-
sion (Figure 4f). Thus suppression of PI3K/AKT activity
mimics the chemoresistant phenotype obtained by miR-205
overexpression.
Figure 4 Exogenous VEGFA/FGF2 attenuates the effect of drug-sensitivity restoration of miR-205 through activating PI3K/AKT signaling in breast cancer cells. (a–c) MCF-7/
A02 and CALDOX cells were stimulated with 30 ng/ml VEGFA or 20 ng/ml FGF2 for 72 h and treated by doxorubicin or taxol. (a) IC50 values of doxorubicin and taxol in
MCF-7/A02-miR-205 cells (upper panels) and CALDOX-miR-205 cells (lower panels) in the presence or absence of VEGFA/FGF2. (b) Caspase-3/7 and caspase-9 activities in
MCF-7/A02 (upper histograms) and CALDOX cells (lower histograms) after 48-h taxol treatment. (c) Expression levels of pAKT, AKT, Bax and Survivin in MCF-7/A02 and
CALDOX with/without miR-205 overexpression in the presence or absence of VEGFA/FGF2 determined by western blotting. (d and e) Cells were treated with PI3K inhibitor
LY294002 (10 μM for MCF-7/A02 and 2 μM for CALDOX) for 24 h and then treated by taxol (0.25 μM for MCF-7/A02 and 2.5 nM for CALDOX) for another 48 h. (d) Annexin V/
propidium iodide staining detected by flow cytometry after 48-h taxol treatment. Representative plots of three independent experiments are shown. Quantitative data show the
average percentage of annexin V-positive cells (both in early apoptosis, lower right quadrants and late apoptosis, upper right quadrants) of three independent experiments (right
panel). (e) Caspase-3/7 and caspase-9 activities in MCF-7/A02 (upper histograms) and CALDOX cells (lower histograms) after 48-h taxol treatment (f) Expression levels of Bax
and Survivin were determined by western blotting in MCF-7/A02 and CALDOX after LY294002 treatment for 48 h. Numerical data represent mean±S.D. based on three
independent experiments (*Po0.05), and the immunoblots are representative of three replicates
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VEGFA and FGF2 protect breast cancer cells from cell
death induced by chemotherapy. To further ascertain
whether VEGFA and FGF2 are functionally important for
chemoresistance, drug-naive MCF-7 and Cal51 cells were
treated with doxorubicin or taxol, in the presence or absence
of VEGFA/FGF2. The addition of either VEGFA or FGF2
significantly increased doxorubicin IC50 values in both MCF-7
and Cal51 cells between 1.75- and 4.45-fold (Figure 5a and
Supplementary Figure S3B). Equally, drug-naive cells were
more resistant to taxol in the presence of VEGFA/FGF2, the
IC50 values increasing between 2.01-and 3.58-fold (Figure 5a
and Supplementary Figure S3B). In agreement with these
results, reduced apoptotic levels (Figure 5b), decreased
cleavage of caspase-3 and PARP (Figure 5c) as well as
lowered caspase-3/7 and caspase-9 activities (Figure 5d)
were all observed in both MCF-7 and Cal51 cells in the
presence of VEGFA/FGF2 after taxol treatment (cleaved
caspase-3 and PARP were not determined in MCF-7 cells
because of CASP3 gene deletion). Moreover, the addition of
VEGFA/FGF2 enhanced the levels of phosphorylated-AKT
and survivin expression but downregulated Bax expression
(Figures 5e and f). Thus exogenous VEGFA/FGF2 confers
resistance to chemotherapeutics through enhancing PI3K/
AKT signaling and inhibiting cell apoptosis in breast
cancer cells.
miR-205 upregulation inhibits tumor growth and
enhances breast cancer chemosensitivity to doxorubicin
and taxol in vivo. The regulatory role of miR-205 on drug
sensitivity was further explored using a mouse xenograft
model. For this, MCF-7/A02-miR-NC, MCF-7/A02-miR-205,
CALDOX-miR-NC and CALDOX-miR-205 cells were injected
into the mammary fat pad of nude mice. In the MCF-7
group, tumors overexpressing miR-205 reached approxi-
mately 300 mm3 at day 45 postimplantation, whereas tumors
increased to approximately 1250 mm3 in the control group
Figure 4 Continued
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Figure 5 VEGFA and FGF2 protect breast cancer cells from chemotherapy-induced cell death through PI3K/AKTactivation and apoptosis inhibition. MCF-7 and Cal51 cells
were stimulated with 30 ng/ml VEGFA or 20 ng/ml FGF2 for 72 h and then treated by doxorubicin or taxol for 48 h. (a) IC50 values of doxorubicin and taxol in MCF-7 cells (upper
panels) and Cal51 cells (lower panels) in the presence or absence of VEGFA/FGF2. (b) Annexin V/propidium iodide staining of cells determined by flow cytometry after 48-h taxol
treatment (10 nM for MCF-7 and 2 nM for Cal51). Representative plots of three independent experiments are shown. Quantitative data show the average percentage of annexin
V-positive cells (both in early apoptosis, lower right quadrants and late apoptosis, upper right quadrants) of three independent experiments (right panel). (c) Detection of cleaved
PARP and cleaved caspase-3 by western blotting in Cal51 cell in the presence or absence of VEGFA/FGF2 after 2 nM taxol treatment for 48 h. (d) Caspase-3/7 and caspase-9
activities in MCF-7 and Cal51 cells after 48-h taxol treatment. (e) Expression levels of Bax and survivin in MCF-7 and Cal51 cells determined by qPCR in the presence or absence
of VEGFA/FGF2. (f) Expression levels of pAKT, AKT, Bax and Survivin determined by western blotting in the presence or absence of VEGFA/FGF2. Numerical data represent
mean± S.D. based on three independent experiments (*Po0.05), and the immunoblots are representative of three replicates
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(Figures 6a–c). Remarkably, tumors generated with
CALDOX cells overexpressing miR-205 failed to engraft,
despite the fact that the controls reached approximately
300 mm3 4 weeks postimplantation (Figures 6d and e).
Chemotherapeutic treatment using a combination of doxor-
ubicin and taxol in the MCF-7/A02-miR-NC and MCF-7/A02-
miR-205 mouse groups started at day 15 and was repeated
every 3 days. As expected, the tumor continued to grow in the
MCF-7/A02-miR-NC group, whereas the chemotherapeutic
treatment was much more effective in tumors derived from
MCF-7/A02-miR-205 cells (Figures 6a and b). Furthermore,
consistent with in vitro analyses, tumors generated from
miR-205-overexpressed cells had higher expression of Bax,
as well as lower expression of survivin, than those generated
with control cells (Figure 6f). miR-205-overexpressing tumors
also showed lower human VEGFA and FGF2 mRNA levels,
and thiswas further confirmed at the protein level when human
VEGFA and FGF2 plasma concentrations were determined
(Figure 6g). Altogether, these data strongly support a tumor-
suppressor role and promoter of chemosensitivity for miR-205
by repression of VEGFA and FGF2 and enhancing cell
apoptosis in breast cancer.
Discussion
NAC has become the standard treatment of locally advanced
breast cancer as it can downstage the disease and improve
surgery options.39,40 Increasing efforts to identify patients that
are sensitive or resistant to NAC treatment have highlighted
the need for applicable biomarkers to predict response to NAC
treatment. In this study, we show that miR-205 expression
levels might be useful for predicting response to TAC regimen
as NAC treatment in breast cancer patients. High miR-205
expression in breast cancer tissues strongly associates with
Figure 5 Continued
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Figure 6 MiR-205 impairs the growth of breast cancer xenografts and increases chemosensitivity in vivo. Drug-resistant breast cancer cells stably expressing miR-205 or
vector control (NC) were subcutaneously injected into the fat pad of nude mice (five per group). Fourteen days after implantation, mice were randomly split into two groups and
treated with either vehicle or doxorubicin (1 mg/kg) plus taxol (2.5 mg/kg) every 3 days until they were killed 45 days after implantation, when xenografts were removed. (a) Size of
MCF-7/A02 xenograft tumors after treatment with saline or drugs. Data are mean of tumor volume± S.D. of five tumors per group. (b) Image of tumors from control or miR-205-
overexpressing MCF-7/A02 xenografts harvested at end point. (c) RNA was isolated from tumors and miR-205 was determined by qPCR. The individual tumor expression data
(dots) and the mean values (line) are indicated. (d) Images of representative mice from control and miR-205-overexpressing CALDOX xenograft models. Arrow indicates the
tumor developed only in the control group. (e) Image of tumors from control CALDOX xenografts harvested at day 28 after implantation. (f) RNA was isolated from tumors, and
bax, survivin, VEGFA and FGF2 mRNA expression levels were determined by qPCR. The individual tumor expression data (dots) and the mean values (line) are indicated.
(g) Expression levels of VEGFA and FGF2 determined by ELISA in plasma harvested at end point. The individual tumor expression data (dots) and the mean values (line) are
indicated. *Po0.05
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increased sensitivity to TAC regimen, which is corroborated by
other reports indicating an association between high miR-205
levels and better distant relapse-free survival in breast cancer
patients.32,41
It is well established that miRNAs can function as tumor
suppressors or oncogenes depending on the cellular context
and cancer types.42,43 miR-205 is located in chromosome
1q32.2 and its expression pattern mirrors that of the miR-200
family.44,45 miR-205 is upregulated in the progenitor subpo-
pulation of a mouse mammary epithelial cell line, thus
promoting cell proliferation and tumor initiation through
targeting PTEN.46 However, increasing evidence shows
downregulation of miR-205 in metastatic breast cancer cell
lines, triple-negative breast cancer and metastatic breast
secondary tumors, suggesting a tumor-suppressor role by
reducing cellular proliferation, tumor angiogenesis and
metastasis.32,34,47,48 In addition, miR-205 has been found to
modulate chemosensitivity in several human cancers but has
opposite roles through targeting different genes. In prostate
cancer, reduced expression of E-cadherin leads to docetaxel
insensitivity, which is partially mediated by reduced miR-205
expression.49 miR-205 also enhances cisplatin toxicity in
castration-resistant prostate cancer cells by targeting
RAB27A and LAMP3,50 whereas in lung cancer, miR-205
overexpression is associated with carboplatin insensitivity by
altering the expression of apoptosis-related genes.51 How-
ever, the effect of miR-205 in breast cancer chemoresistance
is still poorly understood. Here, using chemoresistant breast
cancer cell models, we show that miR-205 targets VEGFA as
well as FGF2 mRNA 3′-UTR and represses their expression,
leading to impaired PI3K/AKT signaling and increased
apoptosis both in vitro and in vivo. These findings are further
supported by clinical data indicating that breast cancer
patients with low VEGFA/FGF2 levels tend to achieve better
response to NAC treatment (Figure 3f). Therefore, our study
reveals a novel mechanism for miR-205 as a tumor suppressor
and regulator of chemotherapy response.
miRNAs bind the 3′-UTR of target mRNAs repressing their
translation. As binding to target sequences is not very
stringent, miRNAs have a plethora of potential targets and it
is plausible that additional molecules, other than VEGFA and
FGF2, may be involved in mediating miR-205 chemo-
sensitizing effect. Although we have ruled out ZEB-1 as the
target gene of miR-205 in these two drug-resistant cell lines
in vitro, it is unexpected that miR-205 overexpression in
CALDOX cells leads to the failure of engraftment in vivo.
This suggests that miR-205 may also be suppressing breast
cancer cells’ proliferation or tumorigenesis via additional
mechanisms in line with our data (Figure 2c and Supple-
mentary Figure S1B) and those found in melanoma52 and
osteosarcoma.24
Although VEGFA and FGF2 were initially discovered as two
of the most potent regulators of angiogenesis,53 it has become
apparent that the function of VEGFA and FGF2 is not only
limited to angiogenesis and vascular permeability but also
includes embryogenesis tumor survival, proliferation and
migration.54–56 Moreover, accumulating evidence demon-
strates that VEGFA and FGF2 contribute to cytoprotection
against drug toxicity via regulating apoptotic mediators and
PI3K/AKT signaling pathway and thus has an important role in
cancer drug resistance.37 For instance, loss of VEGFA expres-
sion increases sensitivity to 5-fluorouracil in colorectal cancer by
inducing apoptosis.57 Beside promoting resistance to imatinib in
chronic myeloid leukemia36 and promoting resistance to gefitinib
in non-small cell lung cancer,35 FGF2 expression is also a
stronger predictor of paclitaxel resistance thanP-gp, p53 or Bcl-2
in several cancers.58 Several VEGFA-/FGF2-targeting miRNAs
have been described in different cancers, including miR-503 in
prostate cancer,59 miR-497 in hepatocellular carcinoma60 and
miR-185 in clear cell renal cell carcinoma.61 Here we present
data indicating that miR-205 targets VEGFA and FGF2 in breast
cancer cells leading to decreased activity of PI3K/AKT signaling
pathway, increased apoptosis and restoration of drug sensitivity
in drug-resistant breast cancer cells.
In conclusion, our data demonstrate that elevated miR-205
expression levels enhance sensitivity to TAC chemotherapy in
breast cancer patients. In addition, miR-205-mediated che-
mosensitivity is, at least in part, mediated by downregulation of
VEGFA, FGF2 and subsequent increase of cell apoptosis. The
efficacy of miR-205 in sensitizing breast cancer to chemo-
therapy may also support its application as a potential chemo-
sensitizing agent. Our studies provide the rationale for using
miR-205 as predictive biomarker to stratify patients before
receiving TAC regimen as NAC and developing miR-205-
based therapeutic agents for breast cancer treatment.
Materials and Methods
Patient characteristic, evaluation of treatment response and
sample collection. Clinical data from 30 breast cancer patients who
underwent neoadjuvant treatment from June 2014 to June 2015 are presented in
Table 1. All patients received a TAC regimen of doxorubicin (50 mg/m2, q21d),
docetaxol (75 mg/m2, q21d) and cyclophosphamide (500 mg/m2, q21d) on day 1
after undergoing core needle biopsies of their primary tumors and determination of
the estrogen receptor (ER), progesterone receptor (PR) and Her2 status by
immunohistochemistry. Treatment was continued in the absence of unacceptable
toxicity for six cycles given every 21 days. This study was approved by the Medical
Ethics Committee of Tianjin Medical University Cancer Institute and Hospital, and all
the participants signed written informed consent forms. Because of the small
patient cohort, NAC response rate was calculated as a continuous variable by
determination of the change in the greatest tumor diameter following the formula
(1− greatest tumor diameter after NAC/greatest tumor diameter before NAC) ×
100%. Tumor tissue was obtained by a core biopsy prior to neoadjuvant treatment
and immediately stored at liquid nitrogen. Total RNA was extracted using the
miRCURY RNA Isolation Kit (Exiqon, Vedbaek, Denmark) following the
manufacturer’s instructions.
Cells and drugs. Human breast cancer cell line MCF-7 and its MDR counterpart
MCF-7/A02, human leukemia cell line K562, HL60, BJAB and their MDR counterparts
were gifts from Professor Dongsheng Xiong (Institute of Hematology, PUMC, Tianjin,
China) and were cultured as previously described.21,22 Human breast cancer cell line
Cal51, MTMEC and their MDR counterparts CALDOX and MD60 were cultured as
previously described.17,20 Doxorubicin and taxol were from Sigma (St Louis, MO, USA),
VEGFA and FGF2 from R&D Systems (Oxon, UK) and PI3K inhibitor LY294002 from
Cell Signaling Technology (Danvers, MA, USA).
Plasmids, oligonucleotides and cell transfection. Lentivirus particles
carrying miR-205 cloned into pGLV2-U6-Puro and packaging plasmid mix were
purchased from GenePharma (Shanghai, China). MCF-7/A02 and CALDOX cells
were infected with vector control (NC) or miR-205-overexpression virus and
selected with puromycin as previously described.23 Plasmids (pMir-Target) carrying
VEGFA 3′-UTR or FGF2 3′-UTR downstream from a luciferase gene were
purchased from Life Technologies (Grand Island, NY, USA). phRGTK (Promega,
Madison, WI, USA), expressing Renilla luciferase, was used to normalize for
transfection efficiency essentially as described.23
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Cell viability analysis. MTT (3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetra-
zolium bromide) assays were performed to evaluate the cell growth inhibitory effect
in response to drug treatments and were used to determine the concentration of
drug that inhibited cell growth by 50% (IC50) after 3 days of treatment.
31
Drug resistance clonogenic assay. Cells (1 × 105 per well of a six-well
plate) were treated with a single dose of doxorubicin or taxol for 1 week. Resistant
clones were fixed with 4% paraformaldehyde and stained with 0.2% crystal violet
and counted. Crystal violet retained in the cells was quantified by solubilization with
0.5% acetic acid and measurement of optical density at 592 nm.31
Gene expression analysis. RNA isolation, reverse transcription and real-
time qPCR were performed as previously described23 using specific primers for
each gene (Supplementary Table S3). TaqMan miR-205 and RNU6 RNA (used as a
normalizer) assays (Life Technologies) were used for miR-205 detection.23
Antibodies. Antibodies for immunodetection following immunoblotting
procedures23 were phospho-AKT (D9E), AKT1 (C73H10), Bax (D2E11), cleaved
PARP (D64E10), cleaved caspase 3 (5A1E) (Cell Signalling Technology),
Survivin (ab76424, Abcam, Cambridge, UK) and β-actin (sc47778, Santa Cruz
Biotechnology, Dallas, TX, USA). Appropriate peroxidase-conjugated secondary
antibody (Cell Signaling Technology) were detected by enhanced chemiluminiscence.23
Annexin V staining. Cell apoptosis was measured by flow cytometry using an
annexin V-FITC apoptosis detection kit (Becton–Dickinson, San Diego, CA, USA)
essentially as described.31
Caspase activity. Cells (1 × 104) were incubated with taxol and/or LY294002 in
a 96-well plate for 24 h. Caspase-3/7 and caspase-9 activities were measured using
Caspase-Glo 3/7 Assay and Caspase-Glo 9 Assay Kits, respectively (Promega)
following the protocol recommended by the manufacturer.
Enzyme-linked immunosorbent assay (ELISA). Cells (3 × 105) were
plated in a six-well plate with DMEM medium supplemented with 10% serum and
incubated for 24 h. Medium was replaced with 2 ml serum-free DMEM for another
24 h and then collected for ELISA. Blood was taken from tumor-bearing mice and
immediately placed into EDTA-treated tubes (BD Biosciences, San Jose, CA, USA).
Plasma was obtained by removing blood cells through centrifugation at 1800 × g for
15 min. VEGFA and FGF2 levels in both the cell culture medium and plasma of
mice were measured by commercial VEGFA and FGF2 ELISA Kit (R&D Systems)
according to the manufacturer’s instructions. This kit uses antibodies to recognize
human VEGFA and FGF2 with no cross-reactivity with the mouse corresponding
proteins.
In vivo tumor assay. Cells (5 × 105) were resuspended in a total volume of
100 μl containing 50% Matrigel (BD Biosciences) in PBS and injected into the
mammary fat pad of 4–5-week-old nude mice. Tumor sizes were measured every
3 days in two dimensions using a caliper, and the tumor volume was calculated with
the following formula: tumor volume (mm3)= 0.5 × ab2 (a and b being the longest
and the shortest diameters of the tumor, respectively). Fourteen days after cell
injection, tumor-bearing mice were randomly divided into different groups (five
animals per group) for doxorubicin (1 mg/kg) plus taxol (2.5 mg/kg) treatment or
control (saline). Drug was injected every 3 days, and the tumor volume was
monitored until the mice were killed in a humane manner. Tumors were collected,
RNA was isolated, using a mirVana miRNA Isolation Kit (Life Technologies) following
the manufacturer’s protocol, and gene expression analysis was performed by qPCR.
All animal studies were performed at the National Institutes of Health (Tianjin
Cancer Hospital) in accordance with guidelines under Institutional Animal Care and
Use Committee (IACUC) and approved by the Committee on the Ethics of Animal
Experiments of the Tianjin Cancer Hospital.
Statistical analyses. Statistical analysis was carried out by one-way ANOVA,
and comparisons among groups were carried out by the independent sample two-
sided Student’s t-test. Spearman rank test was used to identify the correlation
between miR-205/VEGFA/FGF2 and NAC response rate, as well as the correlation
between miR-205 and VEGFA/FGF2. All statistical analyses were performed
using the SPSS 22.0 software (SPSS Inc., Chicago, IL, USA). P-valueo0.05 was
considered as statistically significant.
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